LUTATHERA Drug Patent Profile

« Back to Dashboard

When do Lutathera patents expire, and what generic alternatives are available?

Lutathera is a drug marketed by Aaa Usa Inc and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in LUTATHERA is lutetium lu-177 dotatate. Two suppliers are listed for this compound. Additional details are available on the lutetium lu-177 dotatate profile page.

DrugPatentWatch^® Generic Entry Outlook for Lutathera

Lutathera was eligible for patent challenges on January 26, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 25, 2039. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for LUTATHERA

US Patents:	9
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUTATHERA

Paragraph IV (Patent) Challenges for LUTATHERA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUTATHERA	Injection	lutetium lu-177 dotatate	10 mCi/mL	208700	1	2023-11-13

US Patents and Regulatory Information for LUTATHERA

LUTATHERA is protected by nine US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,596,276.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aaa Usa Inc	LUTATHERA	lutetium lu-177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018	AP	RX	Yes	Yes	12,415,003*PED				Y
Aaa Usa Inc	LUTATHERA	lutetium lu-177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018	AP	RX	Yes	Yes	12,161,732*PED				Y
Aaa Usa Inc	LUTATHERA	lutetium lu-177 dotatate	SOLUTION;INTRAVENOUS	208700-001	Jan 26, 2018	AP	RX	Yes	Yes	12,491,272*PED				Y

International Patents for LUTATHERA

When does loss-of-exclusivity occur for LUTATHERA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Croatia

Denmark

European Patent Office

Finland

Germany

Hungary

Israel

Japan

Lithuania

Mexico

Poland

Portugal

Serbia

Singapore

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LUTATHERA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	119655
Australia	2018433575
Australia	2022203683

Supplementary Protection Certificates for LUTATHERA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
4095130	202440024	Slovenia		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; NATIONAL AUTHORISATION NUMBER: EU/1/22/1703; DATE OF NATIONAL AUTHORISATION: 20221209; AUTHORITY FOR NATIONAL AUTHORISATION: EU
4095130	2490022-7	Sweden		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212
4095130	CA 2024 00027	Denmark		PRODUCT NAME: LUTETIUM (177LU) VIPIVOTIDETETRAXETAN; REG. NO/DATE: EU/1/22/1703 20221212

LUTATHERA: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Lutathera (lutetium Lu 177 dotatate) represents a targeted radioligand therapy approved by the FDA in 2018 for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). With its unique mechanism of delivering targeted radiotherapy, Lutathera commands a strong position within the niche oncology market. The compound’s potential extends with expanding indications, increasing demand in neuroendocrine tumor (NET) therapy, and ongoing pipeline development. This analysis explores the investment landscape, market forces, and financial prospects shaping Lutathera's trajectory over the next decade.

---

Summary of Lutathera and Its Market Position

Aspect	Details
Generic Name	Lutetium Lu 177 dotatate
Brand Name	Lutathera
FDA Approval	2018 (for GEP-NETs)
Therapeutic Area	Oncology, Neuroendocrine Tumors
Administration	IV infusion every 8 weeks (4 cycles)
Price per Dose	~$30,000–$40,000 (varies globally)
Market Share (2018–2022)	Estimated 85–90% of peptide receptor radionuclide therapy (PRRT) market in U.S.
Major Manufacturers	Novartis (commercializer), Advanced Accelerator Applications (ARI), others in pipeline

---

Market Dynamics

1. Market Size & Growth Drivers

Parameter	2022 Data	Forecast	Source/Notes
Global Neuroendocrine Tumor Market	$1.5 billion	CAGR: 12% (2023–2030)	[1]
PRRT Segment (Lutathera & competitors)	$600 million	Growing at 15% pa	Assumption based on market reports
Incidence of GEP-NETs	7.9 per 100,000 annually in the U.S.	Increasing trend	[2]

Key Drivers:

• ↑ Incidence and diagnosis rates of neuroendocrine tumors.
• Regulatory approvals expanding indications.
• Increasing adoption of targeted radionuclide therapy.
• Reimbursement policies favoring innovative treatments.

2. Competitive Landscape

Competitors	Products	Market Share	Status	Notes
Lutathera (Novartis)	Lutetium Lu 177 dotatate	85–90%	Market leader	First-in-class PRRT agent
Netspot (Lantheus)	Gallium Ga 68 dotatate	Imaging only	Niche	Diagnostic counterpart
Others	Everolimus, Peptide receptor radionuclide therapies (clinical trials)	Fragmented	Emerging	Pipeline expansion

Competitive advantages of Lutathera include its FDA approval, proven efficacy, and established safety profile; disadvantages involve high costs and logistical challenges.

3. Policies & Reimbursement

Policy Aspect	Details	Impact
FDA	Fast-tracked approval for expanded indications	Accelerates adoption
CMS reimbursement (USA)	Approximately $30,000 per cycle	Positively influences market penetration
Global reimbursement	Varies; supportive in Europe with national health services	Expanding access

---

Financial Trajectory and Investment Outlook

1. Revenue Projections

Year	Estimated Revenue	Basis	Source/Assumption
2023	$500 million	Base case (initial uptake + expansion)	[3]
2025	$750 million	50% growth driven by expanding indications	Assumption
2030	$1.5 billion	Market maturation + global adoption	Conservative estimate

Growth assumptions hinge on approval of second-line indications, broader global reach, and increased adoption in clinical practice.

2. Cost Structure & Profitability

Cost Factors	Approximate % of Revenue	Details
R&D	10–15%	Pipeline development, pipeline expansion
Manufacturing	30–35%	Stable costs due to established production processes
Sales & Marketing	10%	Increasing with market penetration
Regulatory & Compliance	5%	Ongoing

Profitability outlook suggests net margins could be in the 20–30% range by 2025, assuming scale efficiencies and patent protection.

3. Pipeline & Future Indications

Pipeline Candidate	Disease Area	Development Stage	Potential Impact
Lutetium Lu 177 VIP	Small cell lung cancer	Phase II	Major market expansion
Lutetium satrapar	Pancreatic neuroendocrine tumors	Preclinical	Could extend treatment options
Theranostic approaches	Neuroendocrine, prostate, other	Early	Diversify revenue streams

---

Investment Considerations

Factors	Pros	Cons
Market Leadership	First-mover advantage, proven efficacy	Patent expirations possible post-2030
Growth Potential	Indications expansion, pipeline	Regulatory hurdles, high R&D costs
Pricing Power	Reimbursement support	Potential pricing pressures globally
Competitive Landscape	Limited direct competitors currently	Emerging pipeline threats

Comparison with Other Radiopharmaceuticals

Drug	Indications	Price	Year of Approval	Market Size	Major Competitors
Lutathera	GEP-NETs	~$30,000/dose	2018	$600M (segment)	None (first-in-class)
Xofigo (Radium Ra 223)	Prostate cancer	~$10,000/dose	2013	$450M	None
Azedra	Chromaffin tumors	~$70,000/dose	2020	Niche	Limited

---

Regulatory & Legal Landscape

• FDA Approvals & Expansions: 2018 initial approval; ongoing submission for additional indications.
• Orphan Drug Status: Granted for GEP-NETs, extending market exclusivity.
• Patent Portfolio: Focused on compound formulation, delivery systems, and diagnostic companion diagnostics.
• Legal Challenges: Limited patent litigation; potential for biosimilar or generic emergence post-expiry (expected ~2028–2030).

---

Market Trends & Future Outlook

Trend	Impact on Lutathera	Timeline
Personalized Medicine	Enhances demand for targeted therapies	Ongoing
Combination Therapy	Synergies with immunotherapy, chemotherapy	2024–2026
Manufacturing Innovation	Reduced costs, increased scalability	Next 3–5 years
Global Expansion	New markets in Asia, Latin America	Next 2–4 years

---

Comparison with Competing Modalities

Modality	Advantages	Disadvantages	Market Dynamics
Peptide Receptor Radionuclide Therapy (PRRT)	Targeted, high response rates	Logistical complexity	Growing adoption
Chemotherapy	Widely available	Less targeted, toxicity	Declining for GEP-NETs
Immunotherapy	Potential synergy	Limited efficacy in GEP-NETs	Emerging research

---

Key Questions for Investors

• How will expanding indications impact long-term revenue?
• What is the timeline for pipeline candidates to reach commercialization?
• How will competitive innovations or biosimilars influence pricing and market share?
• What policies could alter reimbursement or access?
• How effectively can Novartis execute global commercialization?

Key Takeaways

1. Market Position: Lutathera remains the dominant PRRT agent with an early-mover advantage and significant market share.
2. Growth Potential: Estimated to reach $1.5 billion in revenue by 2030, driven by indication expansion, pipeline development, and increasing NET incidence.
3. Competitive Landscape: Currently limited direct competition, though pipeline threats loom; patent exclusivity and regulatory wins are critical.
4. Financial Outlook: Favorable profit margins projected with economies of scale; R&D investments essential for pipeline success.
5. Investment Risks: Patent expirations, regulatory delays, reimbursement policies, emergence of biosimilars.

---

Frequently Asked Questions (FAQs)

Q1: What are the primary factors influencing Lutathera's market growth?
A1: Incidence of GEP-NETs, regulatory approvals for new indications, reimbursement policies, and increasing adoption of PRRT techniques are vital drivers.

Q2: How does the pipeline impact Lutathera's long-term valuation?
A2: Pipeline candidates targeting other neuroendocrine and solid tumors could significantly expand revenue streams, underpinning future valuation growth.

Q3: What are the main competitive threats?
A3: Emerging radiopharmaceuticals, biosimilars following patent expiry, and combination therapies in clinical development pose challenges.

Q4: How are reimbursement policies expected to evolve?
A4: Favorable reimbursement in core markets like the USA and Europe supports growth; potential reimbursement constraints in emerging markets could slow access.

Q5: What is the estimated timeline for patent expiry and generic entry?
A5: Patent protection is expected through 2028–2030, after which biosimilars may enter, impacting pricing and market share.

---

References

1. "Neuroendocrine Tumor Market Size & Share, 2022–2030," ReportLinker (2022).
2. Modlin IM, et al. "Epidemiology of neuroendocrine tumors.", (2019), Clin Endocrinol.
3. Novartis Annual Report 2022.
4. FDA approval announcement for Lutathera, 2018.
5. "Global Peptide Receptor Radionuclide Therapy Market report," MarketsandMarkets, 2022.

---

Note: Data and projections are based on industry reports, regulatory filings, and market analyses as of early 2023 and subject to change with new developments.